AUSTRALIAN PRODUCT INFORMATION – REPATHA® (EVOLOCUMAB) SOLUTION FOR INJECTION

1. NAME OF THE MEDICINE

Evolocumab

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Repatha is a sterile, preservative-free solution for injection containing 140 mg/mL evolocumab in a pre-filled syringe or pre-filled pen or a 420 mg/3.5 mL solution delivering 120 mg/mL evolocumab in a pre-filled cartridge co-packaged with an automated mini-doser (AMD).

For the full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

Solution for Injection.

Repatha is a sterile, preservative-free solution, clear to opalescent; colourless to yellowish solution for injection, practically free from particles.

4. CLINICAL PARTICULARS

4.1 Therapeutic Indications

Repatha is indicated as an adjunct to diet and exercise in:

<u>Prevention of Cardiovascular Events</u>

Repatha is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke and coronary revascularisation) in adults with established cardiovascular disease in combination with an optimally dosed statin and/or other lipid-lowering therapies (see section 5.1 Pharmacodynamic properties, Clinical trials).

<u>Primary Hypercholesterolaemia</u>

Repatha is indicated in adults with primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia) to reduce low-density lipoprotein cholesterol (LDL-C):

- in combination with a statin or statin with other lipid lowering therapies, or

- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.

Homozygous Familial Hypercholesterolaemia

Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

4.2 Dose and Method of Administration

Dosage (dose and interval)

Primary Hypercholesterolaemia and Prevention of Cardiovascular Events

The recommended dose for Repatha is either 140 mg every 2 weeks or 420 mg once monthly; both doses are clinically equivalent.

Homozygous Familial Hypercholesterolaemia

The initial recommended dose for Repatha is 420 mg once monthly. The dose can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks. Patients on apheresis may initiate treatment with 420 mg every 2 weeks to correspond with their apheresis schedule.

Method of Administration

Administration should be performed by an individual who has been trained to administer the product.

Prior to subcutaneous administration, allow Repatha to sit at room temperature for at least 30 minutes for the pre-filled pen or 45 minutes for the automated mini-doser (AMD). Do not warm in any other way.

Avoid vigorous shaking the product.

Visually inspect the solution for particles and discolouration. Do not use if the solution is discoloured, cloudy, or if flakes or particles are present.

Doses may be administered in the upper arm, thigh, or abdomen. Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red, or hard.

Repatha is for single-use in one patient only. Discard any residue.

Comprehensive instructions for the administration of Repatha are provided in the Instructions for Use.

Indication	Recommended Dosage and Frequency	Method of Administration
Primary Hypercholesterolaemia and Prevention of Cardiovascular Events	140 mg every 2 weeks	One single-use pre-filled pen (SureClick®)
	420 mg once monthly	One single-use automated mini-doser (AMD) with 3.5 mL pre-filled cartridge or Three single-use pre-filled pens (SureClick) administered consecutively within 30 minutes
Homozygous Familial Hypercholesterolaemia	Initial dose is 420 mg once monthly. The dose can be increased to 420 mg every 2 weeks if a clinical meaningful response is not achieved in 12 weeks. Patients on apheresis may initiate treatment with 420 mg every 2 weeks to correspond with apheresis schedule.	One single-use automated mini-doser (AMD) with 3.5 mL pre-filled cartridge or Three single-use pre-filled pens (SureClick) administered consecutively within 30 minutes

Dosage Adjustment

Patients with Renal Impairment

No dose adjustment is necessary in patients with renal impairment.

Patients with Hepatic Impairment

No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Repatha has not been studied in patients with severe hepatic impairment (Child-Pugh class C).

Elderly Patients

No dose adjustment is necessary in elderly patients (age ≥ 65 years).

4.3   Contraindications

Known hypersensitivity to evolocumab or any of the excipients found in Repatha.

4.4   Special warnings and precautions for use

Allergic Reactions

Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha, including some that led to discontinuation of therapy. If signs or

symptoms of serious allergic reactions occur, discontinue treatment with Repatha, treat according to the standard of care, and monitor until signs and symptoms resolve.

Concomitant Lipid-Lowering Therapies

When using Repatha in combination with statins or other lipid-lowering therapies (e.g. ezetimibe), the prescriber should refer to the Contraindications and Special Warnings and Precautions sections of the prescribing information for those medications.

Low LDL-C Levels

Although adverse consequences of very low LDL-C were not identified in the clinical trials with an average exposure of 2 years, the long-term effects of very low levels of LDL-C induced by Repatha are unknown.

Immunogenicity

In clinical studies, 48 patients (0.3%) out of 17,992 patients treated with at least one dose of Repatha tested positive for the development of anti-evolocumab binding antibodies. The patients whose sera tested positive for binding antibodies were further evaluated for neutralising antibodies and none of the patients tested positive for neutralising antibodies. The presence of anti-evolocumab binding antibodies did not impact the pharmacokinetic profile, clinical response, or safety of evolocumab.

Use in Hepatic Impairment

No dose adjustment is necessary in patients with mild to moderate hepatic impairment (Child-Pugh A or B). Repatha has not been studied in patients with severe hepatic impairment (Child-Pugh C).

Use in Renal Impairment

No dose adjustment is necessary in patients with Chronic Kidney Disease (CKD).

Use in the Elderly

Of the 18,546 hypercholesterolaemia patients treated with Repatha in double blind clinical studies, 7656 (41.3%) were ≥ 65 years old, while 1500 (8.1%) were ≥ 75 years old. No overall differences in safety or efficacy were observed between the elderly and younger patients.

Paediatric Use

The safety and effectiveness of Repatha have not been established in paediatric patients with primary hypercholesterolaemia. Fourteen adolescent patients aged 12 years and

over have been included in HoFH clinical studies. No overall differences in safety or efficacy were observed between adolescent and adult patients with HoFH. Long-term safety has not been established in children.

Effects on Laboratory Tests

An integrated safety analysis of phase 2 and 3 randomised controlled studies of Repatha with statin therapy for up to 52 weeks duration was performed to assess alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and creatine kinase (CK) for patients with normal values at baseline. The incidence of ALT or AST > 5-fold the upper limit of normal was 0.1% in both the Repatha (N = 2523) and control (N = 1249) groups. In the same studies, CK > 10-fold the upper limit of normal was 0.2% (N = 2486) in the Repatha group and 0.1% (N = 1217) in the control group.

4.5   Interaction with Other Medicines and Other Forms of Interaction

No formal drug-drug interaction studies have been conducted for Repatha.

The pharmacokinetic interaction between statins and Repatha was evaluated in the Repatha clinical trials. An approximate 20% increase in the clearance of Repatha was observed in patients co-administered with statins. This increased clearance is in part mediated by statins increasing the concentration of PCSK9 which did not adversely impact the pharmacodynamic effect of Repatha on lipids. No statin dose adjustments are necessary when used in combination with Repatha.

4.6   Fertility, Pregnancy and Lactation

Effects on Fertility

No data are available on the effect of Repatha on human fertility. In hamsters, there was no effect on male or female fertility (including oestrous cycling, sperm analysis, mating performance and embryonic development) when evolocumab was administered at dose levels up to 100 mg/kg every 2 weeks (AUC exposure estimate 7-fold higher than in patients receiving Repatha at 420 mg once every 2 weeks). In sexually mature cynomolgus monkeys, no effects were observed on reproductive organ histopathology, menstrual cycling, or sperm parameters following administration of evolocumab at dose levels up to 300 mg/kg weekly for 6 months (AUC exposure up to 133-fold higher than in patients receiving Repatha at 420 mg once every 2 weeks).

Use in Pregnancy

Pregnancy Category: B1

Category B1 refers to drugs where animal studies have not shown evidence of an increased occurrence of foetal damage and which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human foetus having been observed.

In cynomolgus monkeys, no effects on embryo-foetal or postnatal development (up to 6 months of age) were observed when evolocumab was dosed throughout pregnancy at AUC exposure levels 5-fold higher than those achieved in patients receiving Repatha 420 mg once every 2 weeks.

Animal studies are not always predictive of human response. Therefore, it is not known whether Repatha can cause foetal harm when administered to a pregnant woman and Repatha should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

When Repatha is administered with a statin or other lipid-lowering therapies (e.g. ezetimibe) in women of childbearing potential, refer to the Use in pregnancy section of the prescribing information for those medications.

Use in Lactation

It is not known whether Repatha is present in human milk. Many drugs are present in human milk and because of the potential for adverse effects in nursing infants from Repatha, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the potential benefit of the drug to the mother and the potential benefit of breast feeding to the infant.

4.7   Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8   Adverse Effects (Undesirable Effects)

Summary of Safety Profile

The safety of evolocumab was evaluated in 35,141 patients with primary hypercholesterolaemia, 18,546 patients received evolocumab 140 mg every two weeks or 420 mg once monthly representing 32,231 patient-years of exposure with 14,226 patients treated for 12 months or longer. In two clinical studies in 99 patients with homozygous familial hypercholesterolaemia, there were 63 patient-years of exposure to

evolocumab 420 mg every two weeks or once monthly; 23 of them were treated for 12 months or longer. In clinical studies, the incidence of adverse events was similar between evolocumab and control groups. The adverse reactions associated with evolocumab were usually mild to moderate.

Summary of Adverse Events

Adverse events reported by preferred term for patients treated with evolocumab at an incidence rate ≥ 2.0% compared to any control, are shown in Table 1.

Table 1. Adverse Events Occurring in Patients Treated with Evolocumab Compared to Any Control*

Preferred Term Adverse Event	Any control (N = 16,595) %	Evolocumab (N = 18,546) %
Nasopharyngitis	7.1	7.4
Diabetes Mellitus	7.0	6.7
Hypertension	7.6	6.4
Upper Respiratory Tract Infection	4.4	4.6
Back Pain	4.5	4.4
Arthralgia	4.0	3.9
Myalgia	3.8	3.8
Urinary Tract Infection	3.7	3.6
Bronchitis	3.7	3.6
Headache	3.7	3.2
Influenza	2.9	3.2
Diarrhoea	3.0	3.1
Dizziness	2.9	3.0
Cough	3.1	2.9
Angina Pectoris	3.5	2.8
Pain in Extremity	3.1	2.8
Fatigue	2.4	2.3
Muscle Spasms	2.2	2.2

*Any control includes placebo and ezetimibe with or without placebo subjects
N = number of subjects randomised and dosed. Includes Double-Blinded Studies: 20090158, 20090159, 20101154, 20101155, 20110231, 20110109, 20110114, 20110115, 20110116, 20110117, 20120348, 20120356, 20120332 part B, 20110118, 20120153, 20120122

Summary of Adverse Reactions

Adverse reactions are displayed by system organ class and frequency below using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), and very rare (< 1/10,000).

Table 2. Adverse Reactions with Repatha

System organ class (SOC)	Adverse reactions	Frequency category
Gastrointestinal Disorders	Nausea	Common
General Disorders and Administration Site Conditions	Injection Site Reactions[*]	Common
Infections and Infestations	Influenza	Common
	Nasopharyngitis	Common
	Upper Respiratory Tract Infection	Common
Musculoskeletal and Connective Tissue Disorders	Arthralgia	Common
	Back Pain	Common
Skin and Subcutaneous Tissue Disorders	Rash	Common
	Urticaria	Uncommon

[*] Injection Site Reactions includes injection site pain, injection site erythema, injection site bruising, injection site swelling, and injection site haemorrhage

The safety profile in the HoFH population was consistent with that demonstrated in the primary hypercholesterolaemia population.

Other Adverse Reactions

A tabulated listing of adverse reactions reported in < 2% of patients treated with evolocumab to a 0.5% cut off, at an incidence greater than any control, are shown in Table 3.

Table 3. Other Uncommon Adverse Reactions

Body System/Organ Class Adverse Reaction	Any control (N = 16,595) %	Evolocumab (N = 18,546) %
GASTROINTESTINAL DISORDERS		
Abdominal Pain Upper	1.1	1.2
Gastroesophageal Reflux Disease	1.0	1.1
INFECTIONS AND INFESTATIONS		
Sinusitis	1.4	1.5
Gastroenteritis	1.0	1.1
Viral infection	0.4	0.5
METABOLISM AND NUTRITION DISORDERS		
Gout	1.2	1.3
Hyperkalaemia	0.7	0.8
SKIN AND SUBCUTANEOUS TISSUE DISORDERS		
Eczema	0.4	0.6
INVESTIGATIONS		
Blood Creatine Phosphokinase Increased	1.1	1.3
Weight Increased	0.4	0.6
PSYCHIATRIC DISORDERS		
Insomnia	1.0	1.1
CARDIAC DISORDERS		
Palpitations	0.9	1.0
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS		
Epistaxis	0.8	0.9
Oropharyngeal Pain	0.7	0.8
VASCULAR DISORDERS		
Peripheral Arterial Occlusive Disease	0.8	0.9
Intermittent Claudication	0.5	0.6

*Any control includes placebo and ezetimibe with or without placebo subjects.
N = number of subjects randomised and dosed.
Includes Double-Blinded Studies: 20090158, 20090159, 20101154, 20101155, 20110231, 20110109, 20110114, 20110115, 20110116, 20110117, 20120348, 20120356, 20120332 part B, 20110118, 20120153, 20120122

Post marketing Experience

Hypersensitivity reactions including angioedema.

Influenza-like illness

Myalgia

Headache

Reporting of Suspected Adverse Effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at https://www.tga.gov.au/reporting-problems.

4.9   Overdose

There is no specific treatment for Repatha overdose. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5.   PHARMACOLOGICAL PROPERTIES

5.1   Pharmacodynamic Properties

Mechanism of Action

Repatha binds selectively and with high affinity to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated LDLR degradation. Increasing liver LDLR levels results in associated reductions in serum low density lipoprotein-cholesterol (LDL-C).

Pharmacodynamics

Clinical studies have demonstrated that elevated levels of total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), LDL-C and apolipoprotein B (ApoB), the major protein constituent of LDL, promote human atherosclerosis. In addition, decreased levels of HDL-C are associated with the development of atherosclerosis. Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of TC, non-HDL-C, LDL-C, ApoB and lipoprotein(a) [Lp(a)], and inversely with the level of HDL-C. Like LDL, cholesterol-enriched triglyceride-rich

lipoproteins, including very-low density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis. The independent effect of raising HDL-C or lowering triglycerides (TG) or Lp(a) on the risk of cardiovascular morbidity and mortality has not been determined.

In clinical trials, in patients with primary hypercholesterolaemia, Repatha reduced LDL-C, TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/apolipoprotein A1 (ApoA1), VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1.

A single subcutaneous administration of Repatha 140 mg or 420 mg resulted in maximum suppression of circulating unbound PCSK9 by 4 hours followed by a reduction in LDL-C reaching a mean nadir in response by 14 and 21 days, respectively. Changes in unbound PCSK9 and serum lipoproteins were reversible upon discontinuation of Repatha. No increase in unbound PCSK9 or LDL-C above baseline was observed during the washout of evolocumab suggesting that compensatory mechanisms to increase production of PCSK9 and LDL-C do not occur during treatment.

Based on dose-range finding studies, subcutaneous regimens of 140 mg every 2 weeks and 420 mg once monthly were identified as the optimal regimens to achieve maximal LDL-C lowering (Figure 1) and were equivalent in average LDL-C lowering (mean of weeks 10 and 12), resulting in -72% to -57% from baseline compared to placebo. Treatment with Repatha resulted in a similar reduction of LDL-C when used alone or in combination with other lipid lowering therapy. The effect of LDL-C lowering is sustained.

Doses of 140 mg subcutaneously every 2 weeks and 420 mg subcutaneously once monthly achieve approximately 80% of the theoretical maximal reduction in calculated LDL-C at the mean of weeks 10 and 12 based on exposure response models. Intrinsic and extrinsic covariates, such as demographics, co-medications, laboratory variables and disease states are not expected to modify the LDL-C response (see section 4.2 Dose and method of administration).

Figure 1. Effect of Subcutaneous Administration of Repatha 140 mg Every 2 Weeks or 420 mg Once Monthly on LDL-C

Vertical lines represent median values of calculated LDL-C with 25th and 75th percentiles.

Clinical Trials

Summary of Clinical Efficacy

Prevention of Cardiovascular Events

In adults with established cardiovascular disease in combination with a statin and/or other lipid-lowering therapies:

- Repatha significantly reduced the risk for the primary composite endpoint (time to cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation, whichever occurred first) by 15% compared to placebo.

- Repatha reduced the risk of the key secondary composite endpoint (time to cardiovascular death, myocardial infarction, or stroke, whichever occurred first) by 20% compared with placebo.

- 9518 patients treated with Repatha in the cardiovascular outcomes study, achieved at least one LDL-C value < 0.6 mmol/L. These patients had similar

types of adverse events at a similar or lower incidence, compared to patients treated with Repatha or placebo who always had LDL-C ≥ 1.0 mmol/L.

Regression of Atherosclerosis

- In adults with coronary artery disease on lipid-lowering therapy, Repatha reduced percent atheroma volume (PAV) and total atheroma volume (TAV) by 1.01% (0.64, 1.38) and 4.89 mm^3 (2.53, 7.25) respectively from baseline to week 78 compared to placebo (p < 0.0001).

Primary Hypercholesterolaemia

- Repatha reduced LDL-C, TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG, and Lp(a), and increased HDL-C and ApoA1 in patients with primary hypercholesterolaemia.

- Repatha was superior to ezetimibe in reducing LDL-C, TC, ApoB, non-HDL-C, Lp(a), TC/HDL-C, and ApoB/ApoA1.

- Repatha 140 mg every 2 weeks and 420 mg once monthly dosing regimens are clinically equivalent.

- LDL-C reduction of approximately 55% to 75% was achieved with Repatha as early as week 1 and maintained with long-term therapy. Maximal response was generally achieved within 1 to 2 weeks after dosing.

- In 80 to 85% of all patients treated with either dose, Repatha demonstrated a ≥ 50% reduction in LDL-C at the mean of weeks 10 and 12.

- Up to 99% of patients treated with either dose of Repatha achieved an LDL-C of < 2.6 mmol/L and up to 95% patients treated with either dose of Repatha achieved an LDL-C < 1.8 mmol/L at the mean of weeks 10 and 12.

- Repatha was effective in reducing LDL-C regardless of baseline characteristics, with no notable differences observed between subgroups, such as age, race, gender, region, body mass index, National Cholesterol Education Program (NCEP) risk, current smoking status, baseline coronary heart disease (CHD) risk factors, family history of premature CHD, glucose tolerance status (i.e., diabetes mellitus type 2, metabolic syndrome, or neither), hypertension, statin dose and intensity, unbound baseline PCSK9, baseline LDL-C and baseline TG.

Homozygous Familial Hypercholesterolaemia

- Repatha was effective in reducing LDL-C, TC, ApoB, and non-HDL-C in patients with homozygous familial hypercholesterolaemia (HoFH).

- Repatha 420 mg once monthly and 420 mg once every 2 weeks demonstrated a sustained treatment effect as evidenced by a reduction in LDL-C of approximately 20% to 30% in patients with HoFH not on apheresis and approximately 15% to 25% in patients with HoFH on apheresis.

- No overall differences in safety or efficacy of Repatha were observed between adolescent and adult patients with HoFH.

Prevention of Cardiovascular Events

FOURIER was a phase 3, double-blind, randomised, placebo-controlled, event-driven, cardiovascular outcomes study to evaluate the effects of Repatha treatment in adult patients with established cardiovascular disease [prior myocardial infarction (81%), prior non-haemorrhagic stroke (19%), or symptomatic peripheral arterial disease (13%).

Enrolled patients were on a stable background lipid lowering therapy and had LDL-C values ≥ 1.8 mmol/L or non-HDL-C values ≥ 2.6 mmol/L with at least one major or two minor risk factors. Most patients (99.7%) were on a high- (69.3%) or moderate-intensity (30.4%) statin therapy at baseline and most patients (99.6%) were taking at least one other cardiovascular medication such as anti-platelet agents, beta blockers, ACE inhibitors, or angiotensin receptor blockers.

A total of 27,564 patients were randomised 1:1 to receive either Repatha (140 mg every 2 weeks or 420 mg once monthly) or placebo (every 2 weeks or once monthly, respectively) subcutaneously with regular assessments every 12 weeks. Patients were followed for a mean (SD) of 26.1 (6.4) months. A total of 24.6% of patients were female, 85.1% were White, 9.9% were Asian, 2.4% were Black, and 7.9% were Hispanic/Latino. The mean (SD) age was 62.5 (9.0) years. The median (Q1, Q3) LDL-C at baseline was 2.4 (2.1, 2.8) mmol/L.

Repatha significantly reduced the risk for the primary composite endpoint (time to cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation, whichever occurred first) and the key secondary composite endpoint (time to cardiovascular death, myocardial infarction, or stroke, whichever occurred first). No significant difference was observed on cardiovascular or all-cause

mortality; the study was not powered to detect such a difference. The results of primary and secondary efficacy endpoints are shown in Table 4 and Figure 2 and Figure 3 below.

Table 4. Summary of Primary and Secondary Efficacy Endpoints

	Placebo (N = 13,780) n (%)	Repatha (N = 13,784) n (%)	Hazard Ratio[a] (95% CI)	p-value[b]
Primary endpoint (Cardiovascular death, myocardial infarction, hospitalisation for unstable angina, stroke, or coronary revascularisation)	1563 (11.34)	1344 (9.75)	0.85 (0.79, 0.92)	< 0.0001
Key secondary endpoint (Cardiovascular death, myocardial infarction, or stroke)	1013 (7.35)	816 (5.92)	0.80 (0.73, 0.88)	< 0.0001
Other secondary endpoints				
Cardiovascular death	240 (1.74)	251 (1.82)	1.05 (0.88, 1.25)	
Death by any cause	426 (3.09)	444 (3.22)	1.04 (0.91, 1.19)	
First fatal or non-fatal myocardial infarction	639 (4.64)	468 (3.40)	0.73 (0.65, 0.82)	
First fatal or non-fatal stroke	262 (1.90)	207 (1.50)	0.79 (0.66, 0.95)	
First coronary revascularisation	965 (7.00)	759 (5.51)	0.78 (0.71, 0.86)	
First hospitalisation for unstable angina[c]	239 (1.73)	236 (1.71)	0.99 (0.82, 1.18)	

[a] Based on a Cox model stratified by the randomisation stratification factors
[b] 2-sided log-rank test stratified by randomisation stratification factors; Based on pre-specified hierarchical nature of the statistical testing for multiplicity adjustment, the p-values for the primary and key secondary endpoint are statistically significant.
[c] Time to hospitalisation for unstable angina was not a pre-specified endpoint; an ad-hoc analysis was performed to ensure results are provided for each individual component of the primary endpoint.

Figure 2. Cumulative Incidence Estimates for Primary Endpoint (Cardiovascular Death, Myocardial Infarction, Hospitalisation for Unstable Angina, Stroke or Coronary Revascularisation)


Figure 3. Cumulative Incidence Estimates for Key Secondary Endpoint (Cardiovascular Death, Myocardial Infarction or Stroke)

The Kaplan-Meier curves for the primary and key secondary composite endpoints separated at approximately five months and the magnitudes of the absolute risk reductions grew steadily over time.

In an exploratory landmark analysis of post-baseline subgroups, Repatha reduced the risk of the primary and key secondary composite endpoints more after the first year than in the first year of the study.

The efficacy of Repatha on the primary and key secondary composite endpoints was consistent across all pre-specified subgroups (e.g. baseline LDL-C, geographic region, age, sex, race, prior non-haemorrhagic stroke, symptomatic PAD, length of prior

myocardial infarction, intensity of statin treatment at baseline, history of type 2 diabetes, ezetimibe use at baseline) relative to placebo.

Repatha reduced LDL-C by a median (Q1, Q3) of 63.8% (32.3, 76.8) to 69.5% (55.7, 79.1). The treatment difference in LDL-C reduction between Repatha and placebo ranged from 52.1% (95% CI: 49.2%, 55.0%) to 60.7% (95% CI: 60.1, 61.3). These reductions were maintained for more than three years. Corresponding median (Q1, Q3) LDL-C concentrations ranged from 0.7 (0.5, 1.1) mmol/L to 0.9 (0.5, 1.7) mmol/L in the Repatha group and 25% of patients achieved a LDL-C concentration < 0.5 mmol/L.

Of the patients treated with Repatha, 9518 achieved at least one LDL-C value < 0.6 mmol/L. These patients had similar or lower incidence and similar type of adverse events, including neurocognitive events and new onset diabetes, compared to patients treated with Repatha or placebo who always had LDL-C ≥ 1.0 mmol/L.

In a separate study of 1974 patients with established cardiovascular disease enrolled in the FOURIER study, evolocumab was non-inferior to placebo for effects on the cognitive domain of executive function and other cognitive domains, assessed by the CANTAB Spatial Working Memory strategy index of executive function. There was no evidence that Repatha had a detrimental effect on cognitive domains based on the analysis of data from 1204 patients (586 Repatha, 618 placebo).

Effect on LDL-C During Acute Phase of Acute Coronary Syndrome (ACS)

- EVOPACS (Study 12) was an investigator-sponsored, multicentre, double-blind, randomised, placebo controlled, 8-week study conducted in Switzerland of Repatha in 308 patients admitted to the hospital within 24 to 72 hours of an ACS event who received concomitant atorvastatin. Repatha 420 mg once monthly significantly reduced LDL-C from baseline to week 8 compared with placebo (p < 0.001).

- The mean (SD) reduction in calculated LDL-C from baseline at week 8 was 77.1% (15.8%) in the evolocumab group and 35.4% (26.6%) in the placebo group, with a least squares (LS) mean difference (95% CI) of 40.7% (36.2%, 45.2%). Baseline LDL-C values were 3.61 mmol/L in the evolocumab group and 3.42 mmol/L in the placebo group. LDL-C reductions in this study were consistent with previous studies where evolocumab was added to stable lipid-lowering therapy as demonstrated by on-treatment LDL-C levels at week 8 in this study (reflecting steady-state effect of high-intensity statin in both treatment arms) of

0.79 mmol/L and 2.06 mmol/L in the evolocumab plus atorvastatin and the placebo plus atorvastatin groups, respectively.

- The effects of evolocumab in this patient population were consistent with those observed in previous studies in the evolocumab clinical development program and no new safety concerns were noted.

Regression of Atherosclerosis

GLAGOV was a Phase 3, double-blind, randomised, placebo-controlled study to evaluate the effects of Repatha treatment on coronary atherosclerotic disease as measured by intravascular ultrasound (IVUS).

Enrolled patients were required to be on a stable background lipid-lowering therapy and to have a LDL-C ≥ 2.1 mmol/L or LDL-C of ≥ 1.6 to < 2.1 mmol/L with one major or three minor cardiovascular risk factors. These patients had coronary artery disease and required coronary angiography.

A total of 970 patients were randomised 1:1 into two treatment groups to either receive Repatha 420 mg once monthly or placebo once monthly as subcutaneous injections for 76 weeks. IVUS was performed at baseline and at week 78. A total of 27.8% of patients were female and 93.8% were white. The mean (SD) age was 59.8 (9.2) years. The mean (SD) LDL-C at baseline was 2.4 (0.7) mmol/L.

Repatha reduced the percent atheroma volume (PAV) and total atheroma volume (TAV) by 1.01% (0.64, 1.38) and 4.89 mm^3 (2.53, 7.25) respectively from baseline to week 78 compared with placebo (p < 0.0001). Atherosclerosis regression, defined as any reduction in PAV or TAV at week 78, was observed in 17% and 12.5% more patients treated with Repatha than patients treated with placebo for PAV and TAV respectively. The results of the study are shown in Table 5 below.

Table 5. Summary of Efficacy Results

Endpoint	Summary Type	Placebo QM (N = 423)	Repatha 420 mg QM (N = 423)	Treatment Difference (Repatha – Placebo)	P-value on Treatment Difference
Change in PAV (%)[a]	Adjusted Mean (95% CI)	0.05 (-0.32, 0.42)	-0.95 (-1.33, -0.58)	-1.01 (-1.38, -0.64)	< 0.0001
Change in TAV (mm³)[b]	Adjusted Mean (95% CI)	-0.91 (-3.29, 1.47)	-5.80 (-8.19, -3.41)	-4.89 (-7.25, -2.53)	< 0.0001
Regression in PAV [b]	n (%) (95% CI)	200 (47.3) (42.6, 52.0)	272 (64.3) (59.6, 68.7)	17.0 (10.3, 23.5)	< 0.0001
Regression in TAV [b]	n (%) (95% CI)	207 (48.9) (44.2, 53.7)	260 (61.5) (56.7, 66.0)	12.5 (5.8, 19.1)	0.0002

QM = once monthly
[a]Primary endpoint
[b]Secondary endpoint

Exploratory endpoints showed the treatment difference in LDL-C reduction between Repatha and placebo was 68.7 (95% CI: 64.7, 72.7) from baseline to week 78. These reductions were maintained through the end of the study. Corresponding mean (SD) LDL-C concentrations at week 78 were 0.8 (0.7) mmol/L in the Repatha group.

Clinical trials for Primary Hypercholesterolaemia

**Combination with statin or statin with other lipid lowering therapies**

LAPLACE-2 was an international, multicentre, double-blind, randomised, 12-week study of Repatha in 1896 patients with primary hypercholesterolaemia who were randomised to receive Repatha in combination with statins (rosuvastatin, simvastatin or atorvastatin). Repatha was compared with placebo for the rosuvastatin and simvastatin groups and compared with placebo and ezetimibe for the atorvastatin group.

In LAPLACE-2, Repatha exhibited consistent treatment effects of lowering LDL-C and improving other lipid parameters across all statins and statin doses that were evaluated.

Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with placebo for the rosuvastatin and simvastatin groups and compared to placebo and ezetimibe for the atorvastatin group (p < 0.001) (Figure 4). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a) and increased HDL-C from baseline to mean of weeks 10 and 12 as compared with placebo for the rosuvastatin and simvastatin groups (p < 0.05) and significantly

reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a) compared with placebo and ezetimibe for the atorvastatin group (p < 0.001).

Figure 4. Effect of Repatha on LDL-C when Combined with Statins – Mean LDL-C Percent Change from Baseline of Weeks 10 and 12*

*All differences compared with placebo and ezetimibe are statistically significant (p < 0.001).
Vertical lines represent the 95% confidence interval around the mean differences of Repatha compared with control.

In a pre-specified analysis of LAPLACE-2, Repatha significantly reduced LDL-C, TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a) and increased HDL-C and ApoA1 from baseline to mean of weeks 10 and 12 compared with placebo for the combined rosuvastatin, simvastatin and atorvastatin groups (p < 0.001)(Table 6). Consistent treatment effects were observed in an analysis of Repatha compared with ezetimibe for the combined atorvastatin treatment groups (Table 7).

RUTHERFORD-2 was an international, multicentre, double-blind, randomised, placebo-controlled, 12-week study of Repatha in 329 patients with heterozygous familial hypercholesterolaemia (HeFH) on lipid-lowering therapies. Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12, compared with placebo (p < 0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG, and Lp(a), and increased HDL-C and ApoA1 from baseline to mean of weeks 10 and 12 compared with placebo (p < 0.05) (Table 6).

Table 6. Treatment Effects of Repatha Compared with Placebo in Patients with Primary Hypercholesterolaemia - Mean Percent Change from Baseline to Average of Weeks 10 and 12 (%, 95% CI)

Study	Dose regimen	LDL-C (%)	Non-HDL-C (%)	ApoB (%)	TC (%)	Lp(a) (%)	VLDL-C (%)	HDL-C (%)	TG (%)	ApoA1 (%)	TC/ HDL-C Ratio (%)	ApoB/ ApoA1 Ratio (%)
LAPLACE-2 (Combined rosuvastatin, simvastatin, & atorvastatin groups)	140 mg Q2W (N=555)	-72[b] (-75, -69)	-60[b] (-63, -58)	-56[b] (-58, -53)	-41[b] (-43, -39)	-30[b] (-35, -25)	-18[b] (-23, -14)	6[b] (4, 8)	-17[b] (-22, -13)	3[b] (1, 5)	-45[b] (-47, -42)	-56[b] (-59, -53)
	420 mg QM (N=562)	-69[b] (-73, -65)	-60[b] (-63, -57)	-56[b] (-58, -53)	-40[b] (-42, -37)	-27[b] (-31, -24)	-22[b] (-28, -17)	8[b] (6, 10)	-23[b] (-28, -17)	5[b] (3, 7)	-46[b] (-48, -43)	-58[b] (-60, -55)
RUTHERFORD-2 (HeFH)	140 mg Q2W (N=110)	-61[b] (-67, -55)	-56[b] (-61, -51)	-49[b] (-54, -44)	-42[b] (-46, -38)	-31[b] (-38, -24)	-23[b] (-29, -16)	8[b] (4, 12)	-22[b] (-29, -15)	7[a] (3, 12)	-47[b] (-51, -42)	-53[b] (-58, -48)
	420 mg QM (N=110)	-66[b] (-72, -61)	-60[b] (-65, -55)	-55[b] (-60, -50)	-44[b] (-48, -40)	-31[b] (-38, -24)	-16[b] (-23, -8)	9[b] (5, 14)	-17[b] (-24, -9)	5[a] (1, 9)	-49[b] (-54, -44)	-56[b] (-61, -50)
MENDEL 2 (Monotherapy)	140 mg Q2W (N=153)	-57[b] (-61, -54)	-49[b] (-52, -46)	-47[b] (-51, -44)	-35[b] (-37, -32)	-25[b] (-31, -18)	0 (-7, 7)	6[b] (3, 9)	0 (-8, 7)	3[a] (1, 6)	-39[b] (-42, -36)	-49[b] (-53, -45)
	420 mg QM (N=153)	-60[b] (-63, -56)	-53[b] (-56, -50)	-51[b] (-54, -48)	-37[b] (-40, -35)	-26[b] (-33, -19)	-22[b] (-31, -13)	9[b] (6, 12)	-22[b] (-31, -13)	5[b] (2, 8)	-46[b] (-49, -42)	-55[b] (-59, -51)

Key: Q2W = once every 2 weeks, QM = once monthly, HeFH = Heterozygous familial hypercholesterolaemia; [a] p-value < 0.05 when compared with placebo. [b] p-value < 0.001 when compared with placebo.

Statin-intolerant Therapy

GAUSS-2 was an international, multicentre, double-blind, randomised, ezetimibe-controlled, 12-week study of Repatha in 307 patients who were statin-intolerant or unable to tolerate an effective dose of a statin. Repatha significantly reduced LDL-C compared to ezetimibe (p < 0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, and Lp(a) from baseline to mean of weeks 10 and 12 compared with ezetimibe (p < 0.001) (Table 7).

Monotherapy

MENDEL-2 was an international, multicentre, double-blind, randomised, placebo and ezetimibe-controlled, 12-week study of Repatha in 614 patients with hypercholesterolaemia. Repatha significantly reduced LDL-C from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001). Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, and Lp(a) from

baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe
(p < 0.001) (Table 6 and Table 7).

Table 7. Treatment Effects of Repatha Compared with Ezetimibe in Patients with Primary Hypercholesterolaemia – Mean Percent Change from Baseline to Average of Weeks 10 and 12 (%, 95% CI)

Study	Dose regimen	LDL-C (%)	Non-HDL-C (%)	ApoB (%)	TC (%)	Lp(a) (%)	VLDL-C (%)	HDL-C (%)	TG (%)	ApoA1 (%)	TC/ HDL-C Ratio (%)	ApoB/ ApoA1 Ratio (%)
LAPLACE-2 (combined atorvastatin groups)	140 mg Q2W (N=219)	-43 (-50, -37)	-34 (-39, -30)	-34 (-38, -30)	-23 (-26, -19)	-30 (-35, -25)	-1 (-7, 5)	7 (4, 10)	-2 (-9, 5)	7 (4, 9)	-27 (-30, -23)	-38 (-42, -34)
	420 mg QM (N=220)	-46 (-51, -40)	-39 (-43, -34)	-40 (-44, -36)	-25 (-29, -22)	-33 (-41, -26)	-7 (-20, 6)	8 (5, 12)	-8 (-21, 5)	7 (2, 11)	-30 (-34, -26)	-42 (-47, -38)
GAUSS-2 (Statin intolerant)	140 mg Q2W (N=103)	-38[b] (-44, -33)	-32[b] (-36, -27)	-32[b] (-37, -27)	-24[b] (-28, -20)	-24[b] (-31, -17)	-2 (-10, 7)	5 (1, 10)	-3 (-11, 6)	5[a] (2, 9)	-27[b] (-32, -23)	-35[b] (-40, -30)
	420 mg QM (N=102)	-39[b] (-44, -35)	-35[b] (-39, -31)	-35[b] (-40, -30)	-26[b] (-30, -23)	-25[b] (-34, -17)	-4 (-13, 6)	6 (1, 10)	-6 (-17, 4)	3 (-1, 7)	-30[b] (-35, -25)	-36[b] (-42, -31)
MENDEL 2 (Monotherapy)	140 mg Q2W (N=153)	-40[b] (-44, -37)	-36[b] (-39, -32)	-34[b] (-37, -30)	-25[b] (-28, -22)	-22[b] (-29, -16)	-7 (-14, 1)	6[a] (3, 9)	-9 (-16, -1)	3 (0, 6)	-29[b] (-32, -26)	-35[b] (-39, -31)
	420 mg QM (N=153)	-41[b] (-44, -37)	-35[b] (-38, -33)	-35[b] (-38, -31)	-25[b] (-28, -23)	-20[b] (-27, -13)	-10 (-19,-1)	4 (1, 7)	-9 (-18, 0)	4[a] (1, 7)	-28[b] (-31, -24)	-37[b] (-41, -32)

Key: Q2W = once every 2 weeks, QM = once monthly [a] p-value < 0.05 when compared with ezetimibe; [b] p-value < 0.001 when compared with ezetimibe.

Long-term Efficacy in Primary Hypercholesterolaemia

DESCARTES was an international, multicentre, double-blind, randomised, placebo-controlled, 52-week study of Repatha in 901 patients with hypercholesterolaemia who were receiving diet alone, atorvastatin, or a combination of atorvastatin and ezetimibe. Repatha 420 mg once monthly significantly reduced LDL-C from baseline at 52 weeks compared with placebo (p < 0.001). Treatment effects were sustained over 1 year as demonstrated by reduction in LDL-C from week 12 to week 52 (Figure 5). Reduction in LDL-C from baseline at week 52 compared with placebo was consistent across background lipid-lowering therapies optimised for LDL-C and cardiovascular risk. Repatha 420 mg once monthly significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C,

ApoB/ApoA1, VLDL-C, TG, and Lp(a), and increased HDL-C at week 52 compared with placebo (p < 0.001) (Table 8).

Table 8. Treatment Effects of Repatha Compared with Placebo in Patients with Primary Hypercholesterolaemia – Mean Percent Change from Baseline to Week 52 (%, 95% CI)

Study	Dose regimen	LDL-C (%)	Non-HDL-C (%)	ApoB (%)	TC (%)	Lp(a) (%)	VLDL-C (%)	HDL-C (%)	TG (%)	ApoA1 (%)	TC/HDL-C Ratio (%)	ApoB/ApoA1 Ratio (%)
DESCARTES	420 mg QM (N=599)	-59[b] (-64, -55)	-50[b] (-54, -46)	-44[b] (-48, -41)	-33[b] (-36, -31)	-22[b] (-26, -19)	-29[b] (-40, -18)	5[b] (3, 8)	-12[b] (-17, -6)	3 (1, 5)	-37[b] (-40, -34)	-46[b] (-50, -43)

Key: QM = once monthly [b] p-value < 0.001 when compared with placebo.

Figure 5. Mean Percent Change from Baseline in Calculated LDL-C by Scheduled Visit and Investigational Product (DESCARTES)

DESCARTES - Full Analysis Set.
N = number of subjects randomised and dosed in the full analysis set.
EvoMab = Repatha; WK = week; QM = once monthly (subcutaneous); MG = milligrams.
Vertical lines represent the standard error around the mean. Plot is based on observed data and no imputation is used for missing values.

OSLER-1 and OSLER-2 were two randomised, controlled, open-label extension studies to assess the long-term safety and efficacy of Repatha in patients who completed treatment in a 'parent' study. In each extension study, patients were randomised 2:1 to receive either Repatha plus standard of care (evolocumab group) or standard of care alone (control group) for the first year of the study. At the end of the first year (week 52 in OSLER-1 and week 48 in OSLER-2), patients were eligible to enter the all Repatha

period in which all patients could receive open-label Repatha for either another 4 years (OSLER-1) or 2 years (OSLER-2).

A total of 1324 patients enrolled in OSLER-1. Repatha 420 mg once monthly reduced LDL-C from baseline at week 12 and week 52 compared with control. Treatment effects were maintained over 272 weeks as demonstrated by a reduction in LDL-C from week 12 in the parent study to week 260 in the open-label extension and the safety profile remained the same. A total of 3681 patients enrolled in OSLER-2. Repatha reduced LDL-C from baseline at week 12 and week 48 compared with control. Treatment effects were maintained as demonstrated by reduction in LDL-C from week 12 to week 104 in the open-label extension. Repatha reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 from baseline to week 52 in OSLER 1 and to week 48 in OSLER-2 compared with control. LDL-C and other lipid parameters returned to baseline within 12 weeks after discontinuation of Repatha at the beginning of OSLER-1 without evidence of rebound.

TAUSSIG was a multicentre, open-label 5-year extension study to assess the long-term safety and efficacy of Repatha in patients with severe familial hypercholesterolaemia (FH), including homozygous familial hypercholesterolaemia (HoFH), who were treated with Repatha as an adjunct to other lipid-lowering therapies. A total of 194 severe FH (non-HoFH) patients and 106 HoFH patients enrolled in TAUSSIG. All patients in the study were initially treated with Repatha 420 mg once monthly except for those receiving lipid apheresis at enrolment, who began with Repatha 420 mg every 2 weeks. Dose frequency in non-apheresis patients could be titrated up to 420 mg once every 2 weeks based on LDL-C response and PCSK9 levels. Repatha demonstrated a sustained treatment effect as evidenced by a reduction of LDL-C in patients with severe FH (non-HoFH) (Table 9). Changes in other lipid parameters (TC, ApoB, non-HDL-C, TC/HDL-C, and ApoB/ApoA1) also demonstrated a sustained effect of ongoing Repatha administration in patients with severe FH (non-HoFH).

Table 9. Effect of Repatha on LDL-C in Patients with Severe FH (non-HoFH) – Mean Percent Change from Baseline to OLE Week 216 (and associated 95% CI)

Patient Population (N)	OLE Week 12 (n=191)	OLE Week 24 (n=191)	OLE Week 36 (n=187)	OLE Week 48 (n=187)	OLE Week 96 (n=180)	OLE Week 144 (n=180)	OLE Week 192 (n=147)	OLE Week 216 (n=96)
Severe FH (non-HoFH) (N = 194)	-54.9 (-57.4, -52.4)	-54.2 (-57.0, -51.3)	-54.7 (-57.4, -52.0)	-56.9 (-59.7, -54.1)	-53.3 (-56.9, -49.7)	-53.5 (-56.8, -50.2)	-48.3 (-53.0, -43.7)	-47.2 (-52.9, -41.5)

OLE = open-label extension. N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific schedule visit (n) in the Severe FH (non-HoFH) Final Analysis Set.

Homozygous Familial Hypercholesterolaemia

TESLA was an international, multicentre, double-blind, randomised, placebo-controlled 12-week study of Repatha in 49 HoFH patients between 12 to 65 years of age (including 10 adolescent patients) evaluated for their response to 420 mg once monthly as an adjunct to other lipid-lowering therapies (e.g. statins, bile-acid sequestrants). Repatha 420 mg once monthly significantly reduced LDL-C and ApoB at week 12 compared with placebo (p < 0.001) (Table 10). Changes in other lipid parameters (TC, non-HDL-C, TC/HDL-C, and ApoB/ApoA1) also demonstrated a treatment effect of Repatha administration in patients with HoFH.

Table 10. Treatment Effects of Repatha Compared With Placebo in Patients With Homozygous Familial Hypercholesterolaemia – Mean Percent Change From Baseline to Week 12 (%, 95% CI)

Study	Dose regimen	LDL-C (%)	Non-HDL-C (%)	ApoB (%)	TC (%)	Lp(a) (%)	VLDL-C (%)	HDL-C (%)	TG (%)	TC/ HDL-C Ratio (%)	ApoB/ ApoA1 Ratio (%)
TESLA (HoFH)	420 mg QM (N=33)	-32[b] (-45, -19)	-30 (-42, -18)	-23[b] (-35, -11)	-27 (-38, -16)	-12 (-25, 2)	-44 (-128, 40)	-0.1 (-9, 9)	0.3 (-15, 16)	-26 (-38, -14)	-28 (-39, -17)

[b] p-value < 0.001 when compared with placebo.

Efficacy in Homozygous Familial Hypercholesterolaemia

In TAUSSIG, Repatha demonstrated a sustained treatment effect as evidenced by reduction of LDL-C in patients with HoFH (overall, non-apheresis, apheresis) (Table 11). Changes in other lipid parameters (TC, ApoB, non-HDL-C, TC/HDL-C, and ApoB/ApoA1) also demonstrated a sustained effect of Repatha administration in patients with HoFH. Reductions in LDL-C and changes in other lipid parameters in 14 adolescent patients (12

to < 18 years of age) with HoFH were comparable to those in the overall HoFH study population.

Table 11. Effect of Repatha on LDL-C in Patients with Homozygous Familial Hypercholesterolaemia – Mean Percent Change from Baseline to OLE Week 216 (and associated 95% CI)

Patient Population (N)	OLE Week 12	OLE Week 24	OLE Week 36	OLE Week 48	OLE Week 96	OLE Week 144	OLE Week 192	OLE Week 216
HoFH (N = 106)	-21.2 (-26.0, -16.3) (n = 104)	-21.4 (-27.8, -15.0) (n = 99)	-27.0 (-32.1, -21.9) (n = 94)	-24.8 (-31.4, -18.3) (n = 93)	-25.0 (-31.2, -18.8) (n = 82)	-27.7 (-34.9, -20.5) (n = 79)	-27.4 (-36.9, -17.8) (n = 74)	-24.0 (-34.0, -14.0) (n = 68)
Non-apheresis (N = 72)	-22.7 (-28.1, -17.2) (n = 70)	-25.8 (-33.1, -18.5) (n = 69)	-30.5 (-36.4, -24.7) (n = 65)	-27.6 (-35.8, -19.4) (n = 64)	-23.5 (-31.0, -16.0) (n = 62)	-27.1 (-35.9, -18.3) (n = 60)	-30.1 (-37.9, -22.2) (n = 55)	-23.4 (-32.5, -14.2) (n = 50)
Apheresis (N = 34)	-18.1 (-28.1, -8.1) (n = 34)	-11.2 (-24.0, 1.7) (n = 30)	-19.1 (-28.9, -9.3) (n = 29)	-18.7 (-29.5, -7.9) (n = 29)	-29.7 (-40.6, -18.8) (n = 20)	-29.6 (-42.1, -17.1) (n = 19)	-19.6 (-51.2, 12.1) (n = 19)	-25.9 (-56.4, 4.6) (n = 18)

OLE = open-label extension. N (n) = Number of evaluable patients (N) and patients with observed LDL values at specific schedule visit (n) in the HoFH Final Analysis Set (overall, non-apheresis, and apheresis).

5.2   Pharmacokinetic Properties

Evolocumab exhibits non-linear kinetics as a result of binding to PCSK9. Administration of the 140 mg dose in healthy volunteers resulted in a C_{max} mean (standard deviation [SD]) of 18.6 (7.3) µg/mL and AUC_{last} mean (SD) of 188 (98.6) day•µg/mL. Administration of the 420 mg dose in healthy volunteers resulted in a C_{max} mean (SD) of 59.0 (17.2) µg/mL and AUC_{last} mean (SD) of 924 (346) day•µg/mL. Following a single 420 mg intravenous dose, the mean (SD) systemic clearance was estimated to be 12 (2) mL/hr. An approximate 2- to 3-fold accumulation was observed in trough serum concentrations (C_{min} [SD] 7.21 [6.6]) following 140 mg doses administered subcutaneously every 2 weeks or following 420 mg doses administered subcutaneously monthly (C_{min} [SD] 11.2 [10.8]), and serum trough concentrations approached steady state by 12 weeks of dosing.

Absorption

Following a single subcutaneous dose of 140 mg or 420 mg Repatha administered to healthy adults, median peak serum concentrations were attained in 3 to 4 days and estimated absolute bioavailability was 72%.

Distribution

Following a single 420 mg Repatha intravenous dose, the steady-state volume of distribution was estimated to be 3.3 (0.5) L, suggesting Repatha has limited tissue distribution.

Metabolism

As a fully human IgG2 antibody, the clearance of Repatha is mediated by specific binding and complex formation with its target ligand, PCSK9, as well as by typical IgG clearance processes in the reticuloendothelial system (RES). Repatha is expected to be degraded into small peptides and amino acids via these catabolic pathways.

Excretion

Repatha was estimated to have an effective half-life of 11 to 17 days.

No time dependent changes were observed in serum evolocumab concentrations over a period of 124 weeks.

An approximate 20% increase in the clearance of Repatha was observed in patients co-administered with statins. This increased clearance is in part mediated by statins increasing the concentration of PCSK9 which did not adversely impact the pharmacodynamic effect of Repatha on lipids. Population pharmacokinetic analysis indicated no appreciable differences in evolocumab serum concentrations in hypercholesterolaemic (non-FH or FH) patients taking concomitant statins (see section 4.5 Interaction with other medicines and other forms of interaction).

Special Populations

Population pharmacokinetic analyses suggest that no dose adjustments are necessary for age, race or gender. The pharmacokinetics of Repatha were influenced by body weight without having any notable impact on LDL-C lowering. Therefore, no dose adjustments are necessary based on body weight.

Hepatic Impairment

Single 140 mg subcutaneous doses of Repatha were studied in 8 patients with mild hepatic impairment, 8 patients with moderate hepatic impairment and 8 healthy subjects. The exposure to evolocumab was found to be approximately 40% to 50% lower compared with healthy subjects. However, baseline PCSK9 levels and the degree and time course of PCSK9 neutralisation were found to be similar between patients with mild

or moderate hepatic impairment and healthy subjects. This resulted in similar time course and extent of absolute LDL-C lowering.

Renal Impairment

Population pharmacokinetic analysis of integrated data from the Repatha clinical trials did not reveal a difference in pharmacokinetics in Chronic Kidney Disease (CKD) patients with stages 2 and 3 renal impairment relative to non-renally impaired patients.

In a clinical trial of 18 patients with either normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m^2), stage 4 CKD (eGFR < 30 mL/min/1.73 m^2) or stage 5 CKD (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m^2 or on dialysis), exposure, as assessed by C_{max}, was found to be approximately 30% to 45% lower in patients with stage 4 or 5 CKD compared with patients with normal renal function. The median t_{max} was similar across all groups. The pharmacodynamics and safety of Repatha in patients with stage 4 or 5 CKD were similar to patients with normal renal function and there were no clinically meaningful differences in LDL-C lowering. Therefore, no dose adjustments are necessary in patients with stage 4 or 5 CKD.

5.3   Preclinical Safety Data

Genotoxicity

The mutagenic potential of Repatha has not been evaluated; however, monoclonal antibodies are not expected to alter DNA or chromosomes.

Carcinogenicity

The carcinogenic potential of Repatha was evaluated in a lifetime study conducted in the hamster at dose levels up to 100 mg/kg every 2 weeks (AUC exposure 7-fold higher than in patients receiving Repatha at 420 mg once every 2 weeks). There were no evolocumab-related tumours. Expected serum LDL-C lowering was observed throughout the study.

6.   PHARMACEUTICAL PARTICULARS

6.1   List of Excipients

Repatha is formulated from proline, glacial acetic acid, polysorbate 80, water for injection and sodium hydroxide.

6.2   Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store refrigerated at 2°C to 8°C in the original carton.

If removed from the refrigerator, Repatha should be kept at controlled room temperature (up to 25°C) in the original carton and must be used within 30 days.

Protect Repatha from direct light and do not expose to temperatures above 25°C.

Do not freeze.

Do not shake.

6.5 Nature and Contents of Container

The needle cover of the glass pre-filled syringe and the pre-filled pen is made from dry natural rubber (a derivative of latex).

Repatha is provided as a:

- 1 mL solution (140 mg/mL evolocumab) in a single-use pre-filled syringe made from type I glass with stainless-steel needle, supplied as a 1-pack.*

    * Not available in Australia

- 1 mL solution (140 mg/mL evolocumab) in a single-use pre-filled pen with type 1 glass syringe and stainless-steel needle; supplied as a 1-pack, 2-pack*, and 3-pack*.

    * Not available in Australia

- 3.5 mL solution (420 mg/3.5 mL evolocumab) delivering 120 mg/mL evolocumab in a single-use pre-filled cartridge assembly made from Crystal Zenith® resin which is co-packaged with an administration device (AMD). The administration device is a compact, sterile, single-use, disposable, injection device intended for use only with the provided 3.5 mL pre-filled cartridge assembly; supplied as a 1-pack.

### 6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical Structure

Repatha is a fully human immunoglobulin G2 (IgG2) monoclonal antibody with high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). Repatha has an approximate molecular weight of 144 kDa and is produced using recombinant DNA technology in mammalian (Chinese Hamster Ovary, CHO) cells.

Figure 6. Schematic of Repatha Structure

V_H is the variable domain of the heavy chain
C_H1, C_H2, and C_H3 are the constant domains of the heavy chain
V_L is the variable domain of the light chain
C_L is the constant domain of the light chain

CAS number

1256937-27-5

7. MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine (S4)

8.   SPONSOR

Amgen Australia Pty Ltd

ABN 31 051 057 428

Level 11, 10 Carrington Street

Sydney

NSW 2000

Medical Information: 1800 803 638

Email: medinfo.JAPAC@amgen.com

9.   DATE OF FIRST APPROVAL

9 December 2015

10.   DATE OF REVISION

16 March 2022

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
5.1 Pharmacodynamic properties	Summary of clinical efficacy – addition of clinical trial data under "Effect on LDL-C during acute phase of acute coronary syndrome (ACS)". Addition of text under "Long term efficacy in primary hypercholesterolaemia" to indicate the safety profile remained the same throughout the OSLER-1 treatment period.
Multiple sections	Minor editorial and typographical corrections.